Since GKRP disruptors have been expected as a potential new class of glucose-lowering drugs 61, the action of GKRP in islets should be taken into account for these agents in treating type 2 diabetes mellitus. The gene discussed is GCKR; the disease is type 2 diabetes mellitus.